Health
Moderna Shaves Off $7 Billion in Value After Pfizer Warning
- Stock plunged as rival noted declining demand for Covid shots
- Half of Wall Street analysts rate Moderna shares a buy
This article is for subscribers only.
The pandemic officially ended months ago, allowing a weary public to get back to normal living. That was great news for large swaths of the economy.
But not all of it. Moderna Inc., which shot to fame when it became one the first companies to bring the world Covid-19 vaccines, has been searching for its next big thing ever since. Investors have bailed in droves as waning demand for shots and treatments for the virus drove an eight-day losing streak in the stock.